| Title |
Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, August 2017
|
| DOI | 10.1007/s00262-017-2042-7 |
| Pubmed ID | |
| Authors |
Kar Muthumani, Liron Marnin, Sagar B. Kudchodkar, Alfredo Perales-Puchalt, Hyeree Choi, Sangya Agarwal, Veronica L. Scott, Emma L. Reuschel, Faraz I. Zaidi, Elizabeth K. Duperret, Megan C. Wise, Kimberly A. Kraynyak, Kenneth. E. Ugen, Niranjan Y. Sardesai, J. Joseph Kim, David B. Weiner |
| Abstract |
Prostate-specific membrane antigen (PSMA) is expressed at high levels on malignant prostate cells and is likely an important therapeutic target for the treatment of prostate carcinoma. Current immunotherapy approaches to target PSMA include peptide, cell, vector or DNA-based vaccines as well as passive administration of PSMA-specific monoclonal antibodies (mAb). Conventional mAb immunotherapy has numerous logistical and practical limitations, including high production costs and a requirement for frequent dosing due to short mAb serum half-life. In this report, we describe a novel strategy of antibody-based immunotherapy against prostate carcinoma that utilizes synthetic DNA plasmids that encode a therapeutic human mAb that target PSMA. Electroporation-enhanced intramuscular injection of the DNA-encoded mAb (DMAb) plasmid into mice led to the production of functional and durable levels of the anti-PSMA antibody. The anti-PSMA produced in vivo controlled tumor growth and prolonged survival in a mouse model. This is likely mediated by antibody-dependent cellular cytotoxicity (ADCC) effect with the aid of NK cells. Further study of this novel approach for treatment of human prostate disease and other malignant conditions is warranted. |
X Demographics
The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 24% |
| United Kingdom | 2 | 12% |
| Spain | 2 | 12% |
| Ireland | 1 | 6% |
| Philippines | 1 | 6% |
| Unknown | 7 | 41% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 82% |
| Scientists | 2 | 12% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 58 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 24% |
| Other | 8 | 14% |
| Student > Bachelor | 7 | 12% |
| Student > Ph. D. Student | 7 | 12% |
| Student > Master | 6 | 10% |
| Other | 8 | 14% |
| Unknown | 8 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Immunology and Microbiology | 11 | 19% |
| Biochemistry, Genetics and Molecular Biology | 11 | 19% |
| Medicine and Dentistry | 7 | 12% |
| Agricultural and Biological Sciences | 6 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 6 | 10% |
| Unknown | 15 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 72. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 April 2022.
All research outputs
#540,389
of 23,923,788 outputs
Outputs from Cancer Immunology, Immunotherapy
#17
of 2,897 outputs
Outputs of similar age
#12,217
of 321,270 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#2
of 20 outputs
Altmetric has tracked 23,923,788 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,897 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,270 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.